---
title: "OPM plans to issue additional shares to acquire 100% equity of CRO company Pengli Biotechnology to enhance its overseas influence, resuming trading on February 10"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/227504536.md"
description: "OPM plans to acquire 100% equity of CRO company Pengli Biotechnology through a private placement and cash payment, with an issuance price of 32.00 yuan per share. This move aims to enhance the company's influence in overseas markets, integrate resources, strengthen profitability, and form a dual-driven development pattern of \"products + services.\" After the transaction is completed, the company will further optimize operational management and enhance its market position. The stock is expected to resume trading on February 10, 2025"
datetime: "2025-02-07T09:40:05.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/227504536.md)
  - [en](https://longbridge.com/en/news/227504536.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/227504536.md)
generator: "portal-rs"
---

# OPM plans to issue additional shares to acquire 100% equity of CRO company Pengli Biotechnology to enhance its overseas influence, resuming trading on February 10

According to the Zhitong Finance APP, OPM (688293.SH) has announced a plan to issue shares and pay cash to acquire assets and raise supporting funds. The listed company intends to issue shares and pay cash to 31 counterparties including PL HK, Jiaxing Huituo, Sequoia Hengchen, Shanghai Jingshu, Gu Sheng Investment, TF PL, Hillhouse Chenjun, Hangzhou Tiger, Nantong Dongzheng, Jiangxi Jilin, CICC Qichen, Jiaxing Hetuo, Suzhou Chenling, Mifang Kangjian Venture Capital, Pingyang Guokai, Mifang Pharmaceutical Venture Capital, Wuhan Taiming, Shanghai Jingdu, Wang Guoan, Shanghai Beijiwen, Shanghai Yansheng, Hillhouse Qirui, Zhuhai Liangheng, Jiaxing Yuanlai, Shanghai Junpeng, Xiamen Yinglian, Shanghai Chengxi, Qingdao Qiandao, Shanghai Licheng, Suzhou Guofa, and Qian Tingzhi to purchase 100.00% of the equity of Pengli Bio and raise supporting funds. The issue price is 32.00 yuan per share.

It is reported that Pengli Bio focuses on innovative drug preclinical CRO technical services, especially having a strong competitive advantage in preclinical pharmacology and pharmacokinetics research, making it an important participant in the early research and development phase of innovative drugs. Through this transaction, the listed company and the target company will effectively combine innovative drug research and development with process production, forming significant synergies in business and customer collaboration, overseas strategic layout collaboration, and operational management system collaboration, achieving complementary advantages.

After the completion of this transaction, the listed company's "product + service" dual-drive development pattern will be further improved, deepening its ability to provide one-stop products and services for biopharmaceutical customers, enhancing profitability and strengthening customer stickiness. At the same time, the listed company will be able to integrate the target company's mature international business development team and leverage its established good cooperative relationships with multinational pharmaceutical companies to accelerate the promotion of its culture medium products and services in overseas markets, effectively enhancing the listed company's brand influence and market share in overseas markets. Finally, by drawing on the target company's excellent operational management system and further optimizing resource allocation, the competitiveness of the listed company's service sector will be significantly enhanced, and its market position will be further highlighted.

According to relevant regulations, after applying to the Shanghai Stock Exchange, the company's stock is expected to resume trading on February 10, 2025 (Monday)

### Related Stocks

- [688293.CN](https://longbridge.com/en/quote/688293.CN.md)
- [399441.CN](https://longbridge.com/en/quote/399441.CN.md)

## Related News & Research

- [Zijin Mining Delivers Strong Profit Surge in First Half of 2026](https://longbridge.com/en/news/296702519.md)
- [Thailand to discuss proposed taxes with gold association this week, Finance Minister says](https://longbridge.com/en/news/296736129.md)
- [LeanDNA Launches Demand Scenario Modeling in APEX, Replacing Spreadsheet Guesswork With Real-Time Production Feasibility](https://longbridge.com/en/news/296950066.md)
- [Cerro de Pasco Resources publishes FY2026 annual report](https://longbridge.com/en/news/296917802.md)
- [04:50 ETAntare launches AI physical security platform, transforming unwatched camera footage into intelligence](https://longbridge.com/en/news/296882907.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**